AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

AnaptysBio Inc.

In a report released yesterday, Anupam Rama from J.P. Morgan maintained a Buy rating on AnaptysBio, with a price target of $70.00. The company’s sh...

J.P. Morgan Sticks to Its Buy Rating for AnaptysBio (ANAB)

AnaptysBio ( ($ANAB) ) just unveiled an update. On May 18, 2026, AnaptysBio, Inc.’s board of directors approved a shift in the company’s fiscal yea...

AnaptysBio Adjusts Fiscal Year-End and Reporting Calendar

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Damora Therapeutics (DMRA), Cormedix (CRMD) and Anap...

Analysts Offer Insights on Healthcare Companies: Damora Therapeutics (DMRA), Cormedix (CRMD) and AnaptysBio (ANAB)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AnaptysBio (ANAB), ProQR (PRQR) and OptimizeRx (OPRX...

Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), ProQR (PRQR) and OptimizeRx (OPRX)

In a report released today, Yasmeen Rahimi from Piper Sandler assigned a Buy rating to AnaptysBio, with a price target of $93.00. Rahimi covers the...

Current Quarter	$-0.32	Next Quarter	$-0.17
Current Year	$-1.8	Next Year	$3.1
QoQ Growth	+46.9%	YoY Growth	+272.2%
3Y EPS CAGR	+53.5%	Target Price	$81.50
Consensus	Buy	Upside	+40.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ANAB	$58.23	-2.48%	106.61K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ANAB	$58.23	-2.5%	106.61K
3
4
5
6

ANAB

ANAB

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get AnaptysBio Inc. Data in Excel

Get AnaptysBio Inc. Data in Excel